The abstract is read at the publisher; the summary is JClub's.
ALK-13743 is a highly selective CDK4 inhibitor with an IC50 of 33 nM for CDK4/Cyclin D1, showing RB-dependent antiproliferative activity in ER+ breast cancer models.
- Why it matters: Approved CDK4/6 inhibitors are limited by toxicities linked to CDK6 inhibition, creating a need for CDK4-selective agents with clearer determinants of response in ER+ disease.
- What they did: The authors synthesized ALK-13743, measured biochemical kinase selectivity, tested antiproliferative effects in isogenic ER+ cell lines (MCF7, T47D) using live-cell imaging, assessed cell-cycle changes by immunoblotting, screened synergy across a 307-drug library, and evaluated efficacy in T47D xenografts.
- The result: ALK-13743 inhibited CDK4/Cyclin D1 (33 nM) while sparing CDK6/Cyclin D3 (99 nM) and other kinases, suppressed growth in CDK4-dependent cells, was blunted by CDK6 overexpression, and produced tumor regression in T47D xenografts.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.